

Table 2. Association of subject characteristics with perceived importance by race

Variable	Non-Hispanic Whites	Non-Hispanic Blacks	Hispanics
Medication beliefs <sup>1</sup>	-0.55 (<0.01)	-0.24 (0.01)	-0.08 (0.46)
Hopeful <sup>1</sup>	0.54 (<0.01)	0.16 (0.09)	0.37 (<0.01)
Worried <sup>1</sup>	-0.27 (0.01)	-0.02 (0.87)	0.05 (0.66)
Trust <sup>1</sup>	0.22 (0.02)	0.33 (0.01)	0.17 (0.11)
Poor self-reported health <sup>2</sup>	1.66 (0.10)	1.19 (0.25)	-1.4 (0.16)
Some college education <sup>2</sup>	-1.16 (0.25)	1.9 (0.06)	0.65 (0.52)
Income <12,000/year <sup>2</sup>	0.38 (0.71)	1.65 (0.11)	0.06 (0.96)
Difficulty paying for meds <sup>2</sup>	0.00 (0.99)	-2.05 (0.04)	-0.42 (0.68)

<sup>1</sup> Correlation coefficient (p value); <sup>2</sup> T-test (p value).

subjects had lower levels of hope compared to Non-Hispanic White subjects (difference between means <0.05). Associations between subject characteristics and perceived importance of taking the medication are presented in Table 2. In a multilinear regression model (including education, difficulty paying for medications, medication beliefs, trust, hope and worry), hope was associated with perceived importance of taking the medication in all three ethnic groups. Additional findings differed by race, with medication beliefs in Non-Hispanic White subjects; difficulty paying for medications in Non-Hispanic Black subjects, and worry in Hispanic subjects being associated with perceived importance of taking the medication.

**Conclusions:** Our findings confirm the important influence of emotion on decision making, and suggest that while hope is universally associated with perceived importance of taking a medication, other factors differed, highlighting differences in the decision making process across ethnic groups.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.2369

#### AB1106 VERBAL PATIENT EDUCATION ON VACCINATION IN ADULTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES: IS IT ENOUGH TO IMPROVE VACCINATION RATES?

R. Magro, M. Rogers, F. Camilleri. *Rheumatology, Mater Dei Hospital, Msida, Malta*

**Background:** Patients suffering from autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of infections, due to the underlying condition and its treatment. A study on vaccination in AIIRD carried out at Mater Dei Hospital, Malta in 2015, showed that 37.9% of the patients received the influenza vaccine in the previous year and 8.3% had received the pneumococcal vaccine ever. Only 38.3% knew that they had an increased risk of infection because of their condition.

**Objectives:** The aim of the current study was to establish whether verbal education on vaccination, influenced patients' vaccination rates in the following year. A further aim was to determine whether the patients had a better understanding of their increased infection risk following verbal education.

**Methods:** The initial study carried out in 2015 consisted of a short face-to-face interview with 60 patients who suffered from autoimmune inflammatory rheumatic diseases. Following the interview, verbal information was given to the patients on their increased risk of infection, and the importance of vaccination, in particular the influenza and pneumococcal vaccine. After 1 year, the patients were contacted by means of a telephone call. They were interviewed with regards to their vaccination history and knowledge of their infection risk. Of the 60 patients, 2 had passed away. Therefore 58 patients were included in the study.

**Results:** The study included patients with a variety of AIIRD including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. 60.3% were females and the mean age was 63.1 years (range 25 to 82 years). Influenza vaccination rates in the previous year improved from 37.9% in 2015 to 41.4% in 2016 ( $p=0.704$ ). Pneumococcal vaccination rates improved from 6.9% to 17.2% ( $p=0.086$ ). On questioning the patients regarding their knowledge of increased infection risk, there was no improvement following the verbal education. In fact 37.9% of patients questioned in 2015, and 34.5% in 2016 knew that they were at increased risk of infection because of their condition. 33% of patients studied in 2016 could recall that they had been advised to take vaccination because of their underlying condition or treatment. This improved from 7% in 2015 ( $p<0.005$ ). The proportion of patients who could recall the vaccination advice given was significantly higher in those below 61 years ( $p<0.005$ ). However, there were no significant gender difference ( $p=0.147$ ).

**Conclusions:** Verbal education resulted in more patients receiving the pneumococcal vaccination (although not statistically significant because of the small number involved). It also resulted in a significant increase in the number of patients who were able to recall that they were advised to take vaccination because of their condition. However, only 33% could recall this after a year. Verbal education did not effect the number of patients who took the influenza vaccine and the patients' knowledge of their increased infection risk.

This study highlights that verbal education helps to improve vaccination rates in autoimmune inflammatory rheumatic diseases. However, the advice given tends to be forgotten by the majority of patients after one year. Thus repeated verbal education is necessary, particularly in elderly patients. Moreover other methods of education, such as written information in the form of leaflets, may be useful.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.1962

#### AB1107 ASSESSMENT OF AGREEMENT BETWEEN SELF-REPORT INFLAMMATORY ARTHRITIS SYMPTOMS AND CORRESPONDING GP DIAGNOSIS IN PATIENTS WITH PMR

S.L. Hider<sup>1,2</sup>, M. Blagojevic-Bucknall<sup>2</sup>, S. Muller<sup>2</sup>, K. Clarkson<sup>2</sup>, C. Mallen<sup>2</sup>.  
<sup>1</sup>Haywood Academic Rheumatology Centre, Haywood Hospital, Staffordshire;  
<sup>2</sup>Arthritis Research UK Primary Care Centre, Keele University, Keele, United Kingdom

**Background:** Polymyalgia rheumatica (PMR) is the commonest inflammatory condition among those aged 50 years and over, with a lifetime risk of 2.4% in females and 1.7% in males. Seronegative rheumatoid arthritis is an important differential diagnosis. It is thought a proportion of PMR patients develop an inflammatory arthritis, although prevalence estimates vary.

**Objectives:** To determine the proportion of PMR patients (1) reporting symptoms of possible inflammatory arthritis using a validated self-report inflammatory arthritis algorithm; and (2) who subsequently receive a diagnosis of inflammatory arthritis in their primary care medical records.

**Methods:** A cross-sectional questionnaire study was developed to investigate impact of PMR in primary care patients. All eligible adults aged  $\geq 50$  years, registered with one of 150 participating practices with a first ever Read coded diagnosis of PMR in the last 3 years were mailed a questionnaire including items about socio-demographics, PMR characteristics, joint problems and comorbid conditions. Self-reported inflammatory arthritis (IA) was defined using a validated scoring algorithm (1) with positive responses coded as 1 and negative responses as -1; a score  $>0$  is regarded as predictive of IA. IA score was calculated for those patients that had complete data on all required variables. A list of Read Codes relating to inflammatory arthritis, compiled by a rheumatologist and a GP, were searched for in primary care medical records of consenting respondents. Period of interest was from date of first ever PMR diagnosis in the medical records until survey mail-out.

**Results:** 704 eligible patients were identified and sent a questionnaire, with 550 (78%) responding. Responders and non-responders did not differ significantly by age or gender. Medical records could be obtained for 385 patients, of whom 310 completed the questionnaire fully and were included in the analysis. IA score ranged from -8.4 to 2.5, with 21 (7%) patients being classed as having a positive IA score. 8 out of 310 patients had at least one inflammatory arthritis Read code recorded from date of first diagnosis of PMR in their medical record, although only 2 of these also fulfilled the self-report IA criteria.

**Conclusions:** In this PMR cohort the proportion subsequently diagnosed with an inflammatory arthritis was low (2.5%) although more patients reported inflammatory symptoms. The agreement between self-reported inflammatory symptoms and Read Code diagnosed inflammatory arthritis was low.

**References:**

[1] Tavares R, Wells GA, Bykerk VP et al. A parallel group cohort to determine the measurement properties of an early inflammatory arthritis detection tool. *Rheumatology* 2013;52:2077-2085.

**Acknowledgements:** This study represents independent research funded by the National Institute for Health Research (NIHR). CDM is funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research and a NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). The views expressed are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.5271

#### AB1108 HANDLING OF DE NOVO ARTHRITIS IN ADULTS BY GENERAL PRACTITIONERS: A SURVEY IN A FRENCH COHORT

S. Lecauchois<sup>1</sup>, S. Gentile<sup>2</sup>, P. Champsaur<sup>3</sup>, J.-P. Mattei<sup>4</sup>, L. Dillinger<sup>5</sup>, V. Goeb<sup>6</sup>, S. Guis<sup>4,7</sup>. <sup>1</sup>Aix Marseille Université, AP-HM, Marseille Cedex 9, France; <sup>2</sup>Public Health; <sup>3</sup>Radiology; <sup>4</sup>Rheumatology, Aix Marseille Université, AP-HM, Marseille Cedex 9; <sup>5</sup>General Practitioner, Aix-en-Provence; <sup>6</sup>Rheumatology, CHU Amiens, Université de Picardie Jules Verne, Amiens; <sup>7</sup>Crbm-Cemerem UMR 7339, CNRS, Aix Marseille Université, Marseille, France

**Background:** A guide of good clinical practice regarding *de novo* arthritis in adults has been edited.

**Objectives:** The aim of this work is to identify whether the diagnostic and therapeutic tools proposed by general practitioners (GPs) to adults with a *de novo* arthritis is in line with the corresponding recommendations.

**Methods:** A questionnaire regarding the characteristics and the handling of *de novo* arthritis in adults has been submitted to 300 GPs chosen randomly from a French cohort database. The study period was from February 2015 to February 2016. Fifty seven GPs participated in the study (19%).

**Results:** No particular specificity was identified in the GP group. The age of patients ranged between 40 and 75 yo. The prevalence of arthritis was less than 5% among the GPs patients. The relative number of each category of arthritis was rheumatoid arthritis (29%), spondyloarthritis (14%), PPR (8%), other kinds of microcrystalline arthritis: chondrocalcinosis, (38.4%), gout (11.6%).

Joints with mechanic degenerative effusion related to osteo-arthritis might be misdiagnosed as an inflammatory arthritis.

The knee was the most frequently involved joint in arthritis. The initial paraclinical

survey was related to biology. Most of the patients were treated with NSA as an initial intent. A corticoids-based therapy was proposed to 1.4% of the patients and the corresponding specialist was a rheumatologist (98%).

**Conclusions:** The *de novo* arthritis prevalence for GPs is less than 5% with the knee being the most affected joint. Most frequently, GP are faced with gout, rheumatoid arthritis and spondyloarthritis. The handling is in line with the corresponding guide of good clinical practice.

**Disclosure of Interest:** None declared

DOI: 10.1136/annrheumdis-2017-eular.2521

#### AB1109 DOSE DE-ESCALATION IN A SPECIALIZED OUTPATIENT CLINIC ON BIOLOGICAL THERAPY: COST MINIMIZATION OBSERVATIONAL STUDY

S. Manrique-Arija, I. Ureña, F.G. Jimenez-Nuñez, N. Mena-Vazquez, V. Coret, L. Cano-García, M.C. Ordoñez-Cañizares, C.M. Romero-Barco, M. Rojas-Gimenez, C. Domic, C. Fuego, G. Diaz-Cordoves, A. Belmonte, M.V. Irigoyen, A. Ponce, M. Rodriguez-Perez, A. Fernandez-Nebro. *Department of Rheumatology at the University Regional Hospital of Malaga (HRUM). Institute for Biomedical Research in Málaga (IBIMA). Malaga University, Malaga, Spain*

**Objectives:** To estimate the annual cost in the use of biological therapy (BT) in patients with different rheumatic diseases when dose modifications are undertaken in daily clinical practice in a specialized outpatient clinic during 2016 and to compare the results with data obtained in 2013.

**Methods:** *Design:* Cost minimization observational study under conditions of clinical practice. *Patients:* Patients with different rheumatic diseases who come to a specialized outpatient clinic on BT in the Rheumatologic department at a tertiary Spanish hospital (with a tight follow-up) that had been treated with BT under reduced doses during 2016 were collected. *Protocol:* Reductions in treatment dose or dose frequency were established empirically and were carried out by their rheumatologist in those patients who were in remission (DAS 28 <2,6) for at least 6 months without steroids. *Main outcome:* Reduction of annual average cost in euros in BT used in patients who are in dose reduction in clinical practice in 2016. *Secondary outcome:* Differences in annual costs reduction in 2016 compared with 2013. The cost reduction was calculated by comparing the actual expenditure (after modifying treatment dose in clinical practice) with the theoretical costs (official price) in case you had not made the adjustment. *Statistical analysis:* Sample descriptive analysis. Reducing annual absolute costs and by treatment after tapering down doses in clinical practice in 2016 and the differences found between 2013 were calculated.

**Results:** During 2016, the dose of the BT of 168 patients (94 Subcutaneous BT and 74 intravenous BT) were modified in clinical practice after reaching clinical remission: mean of DAS 28 (mean±SD)=2.31±0.76 or BASDAI (mean±SD)=2.15±1.39 without radiographic progression. Most patients were women (n=113;67%) and had rheumatoid arthritis (n=103;62%) and the rest were distributed among: spondyloarthritis (n=28;17%), psoriatic arthritis (n=22;13%), juvenile idiopathic arthritis (n=10;5%) and Systemic Lupus Erythematosus (n=5;3%). No patients treated with certolizumab or anakinra was modified treatment doses. During this period, 5 patients discontinued BT (3 remissions and 2 minor adverse events). Table 1 shows the number of patients by type of BT and costs. The BT dose reduction in clinical practice during 2016 represented a saving of 676,501.67€ and a greater efficiency of treatments while in 2013, only 86 patients (30 etanercept, 15 adalimumab, 16 Infliximab (Remicade), 15 Tocilizumab IV and 55 Rituximab) had a modified dose of BT in clinical practice assuming a saving of 396,995.46€. The difference in the annual cost reductions in 2016 compared to 2013 meant a saving of 279.506,21€ more in the last year. Table 1.

Biological Therapy	Patients with reduced doses	Theoretical Annual costs (Label doses)	Real Annual Costs (Clinical practice doses)	Annual costs reduction 2016
Etanercept	53	582,453.04	317,649.69	264,803.35
Adalimumab	28	343,186.48	217,922.02	125,264.46
Golimumab	3	32,297.46	28,898.76	3,398.70
Tocilizumab sc	9	109,755.36	79,137.42	30,617.94
Tocilizumab iv	15	179,821.23	136,803.11	43,018.12
Abatacept	1	16,512.42	17,410.64	898.22
Infliximab (Remicade)	15	164,589.70	119,720.52	44,869.18
Rituximab	44	286,410.96	122,779.26	163,631.7
<b>Total</b>	<b>168</b>	<b>1,715,026.65</b>	<b>1,040,321.42</b>	<b>676,501.67</b>

**Conclusions:** In rheumatic diseases we may do a dose de-escalation of BT in patients who go into remission and therefore we could reduce the associated costs of BT and being more efficient with the treatments. We believe that it is important to create specialized outpatient clinics on BT where a tight-control management of these patients and an individualized treatment are carried out.

**Disclosure of Interest:** None declared

DOI: 10.1136/annrheumdis-2017-eular.6220

#### AB1110 WHAT CAN GOOGLE TRENDS CAN TELL US ABOUT A DISEASE? BIG DATA TRENDS ANALYSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS

S. Sciascia, M. Radin. *Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Torino, Italy*


**Background:** "Infodemiology" and "infoveillance" are two recent terms created to describe a new developing approach for public health, based on Big Data monitoring and data mining, applicable to provide new insights into unmet needs, such as the epidemiology of an uncommon disease like Systemic Lupus Erythematosus (SLE)[1].

Analysing how people (including patients, researchers, physicians) search and navigate the Internet for health-related information, as well as how they communicate and share this information, can provide valuable insights into health-related behaviour of populations.

**Objectives:** In this study we aimed to investigate trends of Internet search volumes linked to SLE, on-going clinical trials and research developments associated to the disease, using Big Data monitoring and data mining. We also aimed to analyse peak-related information to investigate knowledge translation of novel therapies for SLE and the influence of media on health-related information seeking.

**Methods:** We performed a longitudinal analysis based on the large amount of data generated by Google Trends, scientific search tools (SCOPUS, Medline/Pubmed/ClinicalTrials.gov) considering "SLE", and "lupus" in a 5-year web-based research.

**Results:** We observed an overall higher distribution of search volumes from Google Trends in United States, South America, Canada, South Africa, Australia and Europe (mainly Italy, United Kingdom, Spain, France, Germany), showing a geographically heterogeneity in insight into health-related behaviour of the different populations towards SLE. Data from Medline/Pubmed, SCOPUS and ClinicalTrials.gov were also analysed in order to monitor public health relevant publications and on-going trials. When comparing these results to the distribution of search volumes of Google Trends, we observed an overall similar distribution of Big Data for United States and Europe, while South America, Canada, Australia and South Africa were less represented. We observed a misbalance between search volumes for Google Trends compared to Medline/Pubmed, SCOPUS and ClinicalTrials.gov in some areas, suggesting a recent and expanding interest on SLE-related health issues in some countries.



**Figure 1:** profile plots for relative search volumes. Profile plots show the relative search volumes, from January 2011 to January 2016, for 'Systemic Lupus Erythematosus' using Google Trends (Panel A), ClinicalTrials.gov (Panel B), PubMed (Panel C) and Scopus (Panel D). Date of search 16th October 2016.

**Conclusions:** We observed in some countries a misbalance between the search volumes generated by Google Trends and those analyzed through scientific search tools. This new approach, merging together informatics and epidemiology, is able to investigate health information seeking. In the near future it might give an estimate of the health-related demand and even of the health-related behaviour of patients with SLE.

**References:**

- [1] Eysenbach G. Infodemiology and infoveillance: framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the Internet. *J Med Internet Res* 2009;11:e11. doi:10.2196/jmir.1157.